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Genome-wide association studies (GWAS) have implicated ANK3 as a susceptibility gene
for bipolar disorder (BP). We examined whether epistasis with ANK3 may contribute to the
“missing heritability” in BP. We first identified via the STRING database 14 genes encoding
proteins with prior biological evidence that they interact molecularly with ANK3. We then
tested for statistical evidence of interactions between SNPs in these genes in associa-
tion with BP in a discovery GWAS dataset and two replication GWAS datasets. The most
significant interaction in the discovery GWAS was between SNPs in ANK3 and KCNQ2
(p=3.18×10−8). A total of 31 pair-wise interactions involving combinations between two
SNPs from KCNQ2 and 16 different SNPs in ANK3 were significant after permutation. Of
these, 28 pair-wise interactions were significant in the first replication GWAS. None were
significant in the second replication GWAS, but the two SNPs from KCNQ2 were found
to significantly interact with five other SNPs in ANK3, suggesting possible allelic hetero-
geneity. KCNQ2 forms homo- and hetero-meric complexes with KCNQ3 that constitute
voltage-gated potassium channels in neurons. ANK3 is an adaptor protein that, through
its interaction with KCNQ2 and KCNQ3, directs the localization of this channel in the axon
initial segment (AIS). At the AIS, the KCNQ2/3 complex gives rise to the M-current, which
stabilizes the neuronal resting potential and inhibits repetitive firing of action potentials.
Thus, these channels act as “dampening” components and prevent neuronal hyperactivity.
The interactions between ANK3 and KCNQ2 merit further investigation, and if confirmed,
may motivate a new line of research into a novel therapeutic target for BP.
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INTRODUCTION
Genome-wide association studies (GWAS) offer an unbiased,
high-throughput approach for searching the entire genome to
identify disease-causing variants. This approach has generated
much enthusiasm in the study of complex disorders such as bipo-
lar disorder (BP) that have been more difficult than Mendelian
diseases to genetically map with linkage and candidate gene asso-
ciation approaches. However, there was little agreement in the
findings from the initial GWAS of BP (Craddock and Sklar, 2009).
These initial studies were likely under-powered to identify suscep-
tibility loci for BP. A mega-analysis (Ferreira et al., 2008) addressed
the issue of power by combining several GWAS, and reported
the strongest evidence of an association with ANK3 (rs10994336,
p= 9.1× 10−9). A subsequent community-wide effort to com-
bine GWAS from existing studies of BP, referred to as the Psy-
chiatric GWAS Consortium (PGC), identified several additional
susceptibility loci and provided further evidence for the associa-
tion with ANK3 (rs10994397, p= 7.1× 10−9) (Psychiatric GWAS
Consortium Bipolar Disorder Working Group, 2011). Although
promising, the loci identified thus far from these efforts likely
account for only a small proportion of variation in susceptibility.
Consequently, much of the genetic architecture of this disorder
remains to be elucidated.
The identification of loci that only account for a small propor-
tion of susceptibility to complex disorders appears to be a typical
feature of GWAS of complex disorders. This has led investigators
to question where the missing heritability is (Manolio et al., 2009).
Epistasis, or gene–gene interaction, is one possible explanation for
the so-called missing heritability. Epistasis can be conceptualized
biologically or statistically (Moore and Williams, 2005). Biolog-
ically, it results from physical interactions between DNA, RNA,
or proteins such that the resulting phenotype depends on the
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action of multiple genes. Statistically, it can be defined as a depar-
ture from the additive effects of alleles from different loci with
respect to their contribution to variation in the resulting pheno-
type. Searching only for main effects of loci and ignoring possible
epistasis may reduce power to detect potentially causal variants
(Cordell, 2002). In fact, some researchers have argued that the
lack of replication across studies may be a hallmark of epistasis
(Wade, 2001; Hirschhorn et al., 2002; Moore and Williams, 2002,
2005). Moreover, the detection of epistasis may help reveal poten-
tially meaningful biological mechanisms (Risch, 1990), which is a
central goal of translational research.
The availability of dense SNP maps in GWAS presents the
opportunity to investigate potential epistasis across the entire
genome. However, this is limited by the computational challenge
of testing all possible interactions between SNPs, and the enor-
mous statistical penalty incurred by the multiple testing (Pattin
and Moore, 2008). One strategy for overcoming these limitations
is to condition the search for epistasis on known loci that have
been previously associated with disease. Although this strategy
runs the risk of missing purely epistatic models in which the genes
involved have little or no main effect on disease susceptibility, it
greatly reduces the possible search space, rendering the analyses
more efficient, while still exploiting the vast amount of data avail-
able from the GWAS. A complementary approach to further reduce
the search space involves limiting the analysis to genes whose prod-
ucts are expected to interact based on biological knowledge, such
as protein interaction databases (Emily et al., 2009).
We therefore decided to search for evidence of epistasis in BP by
focusing onANK3. We chose this gene based on the prior evidence
of association with BP, as well as the biological role of its protein
product, which lends itself to this type of analysis. ANK3 belongs to
a family of multifunctional membrane adapter proteins that target
structurally diverse proteins to specialized membrane domains by
linking them to the spectrin-based membrane skeleton (Bennett
and Chen, 2001). We used a novel strategy that combined bioin-
formatics and statistical genetics approaches to test for relevant
interactions withANK3. First, we searched a well-curated protein–
protein interaction database to identify genes encoding proteins
that biological evidence suggests interact molecularly with ANK3.
Then, we tested for congruent statistical evidence of interactions
between ANK3 and these genes using GWAS data. By placing sta-
tistical findings in the context of human biology, we sought to
strengthen the validity of any conclusions and facilitate the trans-
lation of results into potential benefits aimed at prevention and
treatment of the disorder (Pattin and Moore, 2008).
MATERIALS AND METHODS
SAMPLES
Discovery
We tested for statistical evidence of interactions with ANK3
using a GWAS dataset that consisted of two samples collected
by the NIMH Genetics Initiative Bipolar Disorder Consortium,
the Genetic Association Information Network Bipolar Disorder
(GAIN) sample, and the Translational Genomics Research Insti-
tute Bipolar Disorder (TGEN) sample. The methods for collecting,
diagnosing, and genotyping these samples have been described
elsewhere (Dick et al., 2003; Kassem et al., 2006; Smith et al.,
2009). Cases were ascertained from twelve clinical sites across the
United States. They were assessed with the Diagnostic Interview
for Genetic Studies (DIGS) (Nurnberger et al., 1994), and fam-
ily informant data and medical records were obtained. Diagnoses
were assigned following a best-estimate procedure according to
DSM-III-R or DSM-IV criteria. The cases were all Caucasian and
had a diagnosis of BP. Controls were ascertained through the
efforts of the Molecular Genetics of Schizophrenia II (MGS-2)
Collaboration (Sanders et al., 2008). Control subjects completed a
brief psychiatric questionnaire and were excluded if they endorsed
a history of BP, psychosis, or major depression. Cases and controls
were matched on ethnicity, age, and sex. Appropriate IRB approval
was obtained at each collaborating institution, and all subjects
provided informed consent.
The cases and controls from both the GAIN and TGEN sam-
ples were genotyped on the Affymetrix 6.0 array. Quality control
in both samples consisted of dropping subjects with≥5% missing
data, and dropping SNPs with ≥5% missing data, <1% minor
allele frequency, or HWE p-value <10−6 among controls. We
then imputed SNPs in each sample and combined them into one
dataset. We used phased haplotype data from HapMap I and II
release 241 as the reference panel. We used the program BEAGLE
to flip orientation to the positive strand and impute estimated
allelic dosages for autosomal SNPs (Browning and Yu, 2009). We
excluded any SNPs with an imputation r2 < 0.3. The final GAIN-
TGEN GWAS imputed dataset included 2,191 cases and 1,434
controls with data on 3,849,034 total SNPs.
Replication
We used two additional GWAS datasets for replication of the
top findings. These datasets included the Wellcome Trust Case-
Control Consortium (WTCCC) bipolar disorder sample and a
German bipolar disorder sample. Methods for collecting, diag-
nosing, and genotyping both these samples have been described
elsewhere (Fangerau et al., 2004; Wellcome Trust Case Con-
trol Consortium, 2007; McMahon et al., 2010). Appropriate IRB
approval was obtained and all subjects provided informed consent.
In the WTCCC sample, 2,000 cases were ascertained from sites
across the United Kingdom, and assessed with semi-structured
lifetime diagnostic psychiatric interviews (usually the Schedule
for Clinical Assessment in Neuropsychiatry). A diagnosis of BP
was assigned according to Research Diagnostic Criteria. Three
thousand controls were obtained from the 1958 British Cohort
study and UK blood donors. All cases and controls were Cau-
casian. Genotyping was done on the Affymetrix 500K Mapping
Array. Quality control consisted of dropping subjects with ≥5%
missing data, and dropping SNPs with ≥5% missing data rate,
<1% minor allele frequency, <90% quality score, or HWE p-
value <10−6 among controls. After imputation using procedures
identical to those used with the GAIN-TGEN dataset as described
above, there was a total of 1,868 BP cases and 2,996 controls
with data on 3,849,034 SNPs in the final imputed WTCCC
dataset.
Bipolar disorder cases for the German sample were recruited
through hospital admissions and assessed with a structured
1http://hapmap.ncbi.nlm.nih.gov/
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interview. Diagnoses were assigned according to a best-estimate
procedure using DSM-IV criteria. Population-based control sub-
jects were obtained from the PopGen2, KORA3, and Heinz Nixdorf
Recall Study4 cohorts. Genotyping was done on the Illumina
HumanHap550 array. Quality control for this dataset included
dropping subjects with >5% missing data, and dropping SNPs
with >2% missing data, minor allele frequency <2% or HWE
p-value <0.0001. After imputation using procedures identical to
those used with the GAIN-TGEN dataset as described above, there
was a total of 645 BP cases and 1,310 controls with data on
3,849,034 SNPs in the final imputed German dataset.
BIOINFORMATICS RESOURCE
We used the STRING database version 9.05 to identify proteins
with biological evidence for interaction with ANK3 (Jensen et al.,
2009). STRING is a meta-resource of protein–protein interac-
tion databases, based on the union of known physical protein
interactions and curated data from biological pathways. This com-
prehensive tool extracts evidence from MINT, HPRD, BIND, DIP,
BioGRID, KEGG, Reactome, IntAct, EcoCyc, NCI-Nature Pathway
Interaction Database and Gene Ontology (GO) protein complexes.
It also collects evidence of protein interactions via text min-
ing (from SGD, OMIM, The Interactive Fly, and all abstracts on
PubMed) and interaction transfers between organisms, whereby a
pair of interacting proteins found in one organism is predicted
to occur in another organism if the conservation between the
two organisms implies that such a move is justified. Additionally,
STRING supplements these known interactions with a computa-
tional prediction algorithm. All interactions are given a confidence
score according to the joint probabilities from the different lines
of evidence, correcting for randomly observed interactions. These
scores represent an approximation of how likely each association
describes a functional relationship between the two proteins that
is at least as specific as that between any given pair of proteins
that are annotated in the same KEGG pathway (Szklarczyk et al.,
2011).
ANALYSES
We adopted an analytic strategy that utilized both bioinformatics
and statistical methods to identify and validate significant gene–
gene interactions with ANK3 in BP cases. First, we queried the
STRING protein–protein interaction database using ANK3 as the
index to identify all proteins that had biological evidence of inter-
action with it with at least a high confidence score (defined by
STRING to be 0.7000 or greater). Then, we analyzed the GAIN-
TGEN dataset for statistical evidence of gene–gene interactions
associated with BP between ANK3 and genes encoding the pro-
teins identified by STRING. We used logistic regression to test all
possible pair-wise interactions between SNPs in ANK3 and SNPs
in each of the STRING-identified genes, with the gene bound-
aries defined according to the most inclusive RefSeq transcript
(hg18) ±10 kb to include potential regulatory regions. The logis-
tic regression models included terms for each SNP entered as
2www.popgen.de
3www.gsf.de/KORA
4www.recall-studie.uni-essen.de
5http://string-db.org/
allelic dosages representing the estimated number of copies of
the minor allele and an interaction term between the two SNPs.
The models also included terms to control for study site and the
first two principal components (PCs) from a principal compo-
nents analysis (PCA) using Eigenstrat (Price et al., 2006) with
the genome-wide SNP data to assess for population structure
among the samples in the dataset. We obtained the Wald statistic
for the interaction terms, and then used permutation procedures
to evaluate the significance of the interactions. We randomly
permuted the case-control labels in the discovery sample to gen-
erate 1,000 replicates. We re-ran the SNP–SNP interaction tests
in each replicate, and counted how many of the replicates con-
tained SNP–SNP interactions between ANK3 and the STRING-
identified genes that reached a higher level of significance than
what was observed in the original dataset. The total number of
replicates out of 1,000 provided an empirical estimate of the signif-
icance of the identified interactions while accounting for multiple
testing.
We attempted to replicate any SNP pairs that passed the per-
muted p-value threshold, based on the 50th most significant of the
1,000 permuted p-values (permuted p-value of 0.05). We used the
same logistic regression approach in the analysis of the replication
samples as was used in the discovery sample.
RESULTS
A query of the STRING bioinformatics database yielded a total
of 16 known proteins that had strong biological evidence (con-
fidence score> 0.7000) for interacting with ANK3. Two of these
genes (L1CAM and DMD) are located on chromosome X and
were therefore excluded from the analysis, leaving 14 genes
of interest (shown in Table 1). We then analyzed the GAIN-
TGEN dataset to assess the statistical evidence for interactions
between ANK3 and genes encoding each of the 14 identified
proteins in association with BP (Table 2). KCNQ2 was the
most significantly interacting gene, with a minimum p-value
of 3.18× 10−8, making it the only gene to remain significant
after the permutations (permuted p-value= 0.005). In total, 31
SNP pairs between KCNQ2 and ANK3 were significant after
permutation.
Interestingly, the most significant SNP pairs clustered within a
distinct peak (Figure 1), and were driven by two SNPs in KCNQ2:
rs2282150 (an intronic SNP) and rs2297385 (a synonymous cod-
ing SNP), both of which are in perfect LD (r2=D′= 1.0) with
each other. These two SNPs interacted with 16 unique ANK3
SNPs that were all intronic (rs1459730, rs16914687, rs898329,
rs11814450, rs12413770, rs7911285, rs17233373, rs7910984,
rs7093272, rs16914683, rs12413099, rs16914663, rs16914670,
rs12416179, rs16914968, and rs10994334). However, a cluster
of these ANK3 SNPs fell within the boundaries of ankyrin
repeat domains of the protein, which are known to mediate
protein–protein interactions.
Motivated by these results, we sought to replicate the inter-
actions between the 31 SNP pairs in two additional GWAS
datasets. Of these 31 significant SNP pairs, 28 were significant
(p= 0.015–0.048) in the WTCCC sample. The remaining three
were suggestive (p= 0.052–0.078). None of these SNP pairs were
significant in the German dataset. However, interestingly, the
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Table 1 |ANK3-interacting genes identified by STRING, ranked by confidence score.
Gene Score Chr Description
ANK3 – 10 Membrane-cytoskeleton linker. Thought to localize ion channels and cell adhesion molecules at the NoR and AIS
NFASC 0.984 1 Cell adhesion, ankyrin-binding protein. May be involved in neurite extension, axonal guidance, synaptogenesis,
myelination, and neuron-glial interactions
SPTBN4 0.964 19 Participates in the clustering of voltage-gated Na(+) channels and cell-adhesion molecules at the NoR and AIS
SCN2A 0.941 2 Sodium channel, voltage-gated, type II, alpha subunit: mediates the voltage-dependent sodium ion permeability of
excitable membranes
COL17A1 0.857 10 Collagen, type XVII, alpha 1: may play a role in the integrity of hemidesmosome and the attachment of keratinocytes to the
underlying membrane
ARHGEF7 0.833 13 RAC1 guanine nucleotide exchange factor and can induce membrane ruffling. May function in cell migration and as a
positive regulator of apoptosis
CACNA1C 0.819 12 Mediates the entry of calcium ions into excitable cells. Involved in a muscle contraction, hormone or neurotransmitter
release, gene expression, cell motility, cell division, and cell death
NRCAM 0.766 7 Cell adhesion, ankyrin-binding protein involved in neuron-neuron adhesion. May play a role in the molecular assembly of
the NoR
KCNQ2 0.754 20 Probably important in the regulation of neuronal excitability. Joins with KCNQ3 to form a potassium channel with
M-current channel properties, which determines the subthreshold electrical excitability of neurons as well as the
responsiveness to synaptic inputs
SPTA1 0.735 1 Major constituent of the cytoskeletal network, forms the cytoskeletal superstructure of the erythrocyte plasma membrane
SCN5A 0.726 3 See SNC2A description
KCNQ3 0.72 8 See KCNQ2 description
SPTB 0.719 14 See SPTA1 description
SCN8A 0.716 12 Mediates the voltage-dependent sodium ion permeability of excitable membranes
FADD 0.716 11 Apoptotic adaptor molecule, recruits caspase-8 or -10 to the activated Fas or TNFR-1 receptors
*NoR, nodes of ranvier; *AIS, axon initial segment.
Table 2 | Gene-level minimum p-values for interactions with ANK3: results from discovery analysis of GAIN-TGEN sample.
ANK3 interacting genes Top SNP pairs (ANK3 : interacting gene) Observed p-value Permuted p-value
KCNQ2 rs1459730: rs2297385 3.18E−08 0.005
SPTB rs12411730: rs2269304 1.18E−05 0.851
KCNQ3 rs10994284: rs16904603 1.86E−05 0.939
NFASC rs7098008: rs7535098 1.94E−05 0.949
CACNA1C rs1551684: rs10848666 2.51E−05 0.969
SCN8A rs12355908: rs7976351 9.37E−05 0.992
SPTBN4 rs10994198: rs7252109 9.51E−05 0.992
SCN2A rs7901951: rs1439805 9.76E−05 0.992
ARHGEF7 rs12355908: rs7993510 0.000107 0.992
SCN5A rs16915451: rs7645173 0.000124 0.992
NRCAM rs16914794: rs13223414 0.00013 0.992
SPTA1 rs12356776: rs12039268 0.000157 0.992
FADD rs10821672: rs11235564 0.000283 0.992
COL17A1 rs2288359: rs586550 0.00074 0.992
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FIGURE 1 | 3D plots of the most significant p-values (−log10 p>3) in the
GAIN-TGEN discovery sample. Of these, the 31 SNP pairs which were
significant after permutation correction are shown in red and orange dots.
RefSeq gene models representing ANK3 and KCNQ2 are shown on the X
and Z axis, respectively, and the −log10 (p-value) of the interaction tests are
shown on the Y axis.
two driving SNPs from KCNQ2 were both involved in signif-
icant interactions with five other SNPs in ANK3 (p= 0.033–
0.039), suggesting the possibility of allelic heterogeneity. One of
these ANK3 SNPs (rs10994406) is just over 10 kb away from the
ANK3 SNP (rs10994397) implicated in the recently reported PGC
mega-analysis of BP (Psychiatric GWAS Consortium Bipolar Dis-
order Working Group, 2011), and the other four (rs10994180,
rs10740006, rs10821668, and rs10994181) are tightly clustered in a
highly conserved region stretching over 9.5 kb (chr10:61,827,709–
61,837,348) with an average phyloP of 1.37 and encompassing an
unusually large exon (7,811 bp) in one of the ANK3 transcripts
(refseq: NM_020987.3). Two of the SNPs are coding (rs10821668
is a mis-sense and rs10740006 is a synonymous SNP) and the
four closely straddle a DNAse hypersensitive site that harbors a
transcription factor binding region.
DISCUSSION
Several GWAS of BP have been reported, but conclusive findings
have been elusive. Among the most compelling findings to emerge
thus far have implicated the gene ANK3 (Ferreira et al., 2008; Kel-
soe, 2009; Sklar et al., 2011). However, given the observed effect size
on risk of this gene, it likely accounts for only a small portion of
BP heritability. Because of its known role in interacting with other
membrane bound proteins, we examined whether epistasis with
ANK3 might further contribute to susceptibility for BP. We found
compelling biological evidence for interactions between ANK3
and KCNQ2 based on a bioinformatics search using STRING, and
observed congruent statistical evidence of interactions between
these genes in association with BP using GWAS data.
Prior research has demonstrated an intriguing biological rela-
tionship between ANK3 and KCNQ2. ANK3 is a member of the
ankyrin family of proteins that link integral membrane proteins
to the underlying spectrin-actin cytoskeleton. It is expressed in
the central and peripheral nervous system, and helps to regu-
late the distribution of voltage-gated ion channels (Garrido et al.,
2003). In line with this role, ANK3 interacts directly with KCNQ2,
which is expressed in the brain and forms homomeric and het-
eromeric voltage-gated potassium channels with another member
of the KCNQ family, KCNQ3. These channels are referred to as
Kv7.2/Kv7.3. Through this interaction, ANK3 directs the proper
localization of the Kv7.2/Kv7.3 channels to the axonal initial seg-
ment (AIS) of neurons and nodes of Ranvier (Figure 2). Pan
et al. (2006) demonstrated that the concentration of Kv7.2/Kv7.3
at the AIS was abolished in ANK3 knock-out mice, and that a
short motif in the C-terminal, common to both Kv7.2 and Kv7.3,
was found to be responsible for mediating in vivo interactions
with ANK3 and retention of the subunits at the AIS. At the AIS,
Kv7.2/Kv7.3 gives rise to the M-current, which serves to stabi-
lize the neuronal resting potential and inhibit repetitive firing
of action potentials. By doing so, these channels act as “damp-
ening” components and prevent neuronal hyperactivity (Delmas
and Brown, 2005). Interestingly, mutations in KCNQ2 have been
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FIGURE 2 | KCNQ2/3 gene products (Kv7.2 and Kv7.3) form a
heterotetramer channel at the axon initial segments (AISs) and
nodes of Ranvier of neurons. Ankyrin-G (ANK3 gene product) links
Kv7.2 and Kv7.3 to the underlying actin-βIV spectrin cortical
cytoskeleton and mediates their co-localization via ankyrin-binding
motifs at their C-terminal regions.
shown to cause benign familial neonatal convulsions (BFNC), a
rare autosomal dominant inherited form of epilepsy (Singh et al.,
1998).
Several converging lines of evidence suggest that Kv7.2/Kv7.3
channels and their interactions with ANK3 may play a role in the
etio-pathogenesis of BP. Increased excitability of neurons, which is
suppressed by the Kv7.2/Kv7.3 channel M-currents, may be char-
acteristic of manic and/or hypomanic periods of BP (Xie and
Hagan, 1998). In line with this, one study showed that the suppres-
sion of the M-current by KCNQ2 dominant-negative mutations
in a transgenic mouse model led to hyperexcitability of neurons
and morphological changes of the hippocampus, and mediated
a notable decline in cognitive function, and behavioral changes
corresponding to hyperactivity (Peters et al., 2005). Lithium, the
leading mood stabilizer, is thought to work via two mechanisms of
action that may also influence the activity of Kv7.2/Kv7.3 channels.
Lithium inhibits several enzymes involved in inositol recycling,
a crucial step in the synthesis of PIP2, a membrane phospho-
lipid that is essential for Kv7.2 activity and for its regulation by
acetylcholine (Brown and Passmore, 2009). It also inhibits GSK3β
which is responsible for the phosphorylation of Kv7.2/Kv7.3, and
phosphorylation of these channels suppresses the M-currents to
promote neuronal hyperexcitability (Borsotto et al., 2007). Inter-
estingly, ezogabine, which is a recently approved antiepileptic drug
(AED) that targets Kv7.2/Kv7.3 channels, has been shown to have
mood stabilizing properties in animal models (Dencker et al.,
2008; Redrobe and Nielsen, 2009; Dencker and Husum, 2010; Kris-
tensen et al., 2012) and in a small pilot study in humans (Amann
et al., 2006). Finally, a previous genetic study found evidence of an
association between variants in KCNQ2 and BP (Borsotto et al.,
2007), and our group has reported genome-wide significant link-
age of BP with chromosome 8q24 in a region that harbors KCNQ3
(Avramopoulos et al., 2004).
Despite the biological and statistical evidence reported here in
support of a role for interactions between ANK3 and KCNQ2 in
the etio-pathogenesis of BP, there are several limitations of the
study that merit consideration. Foremost among these is the fact
that the same interacting SNP pairs in ANK3 and KCNQ2 were
not implicated in the German replication dataset. It is impor-
tant to remember that the SNPs included in these tests are likely
not causal and may only partially tag the actual causal variants
responsible for disrupting the gene–gene interactions. As a result,
different tagging SNPs may be implicated in the interaction tests
in different datasets. Moreover, it is quite possible that there is
allelic heterogeneity and different causal variants may contribute
to the disruption of the gene–gene interactions in different sam-
ples. To this point, it is interesting to note that of the ANK3 SNPs
implicated in the German dataset, one was located near the SNP
that was most strongly implicated in the PGC mega-analysis of BP,
and the other four clustered in another highly interesting region
of ANK3 that may also have important functional relevance that
needs to be further elucidated.
Another limitation is that we tested for interactions between
SNPs in KCNQ2 and the top SNPs in ANK3 implicated in the
GWAS by Ferreira et al. (rs10994336) (Ferreira et al., 2008) and
in the mega-analysis by the PGC (rs10994397) (Psychiatric GWAS
Consortium Bipolar Disorder Working Group, 2011), but none
of these were notably significant (data not shown). However, as
noted above, a SNP located near the PGC SNP was implicated
in one of our replication datasets. It is also likely that the previ-
ously identified SNPs in ANK3 merely tag the true causally related
variants and are imperfect proxies for them. The causally related
variants in these genes need to be identified before we can more
accurately characterize the nature of their interaction in suscep-
tibility to BP. Toward this end, we are currently participating in
a sequencing study of BP and plan to examine the data from this
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study in order to further examine these interactions. By identifying
the causally related variants, will be able to examine in in vivo and
in vitro models the mechanisms by which they disrupt the interac-
tions between ANK3 and KCNQ2 and contribute to the molecular
underpinnings of BP.
As far as we are aware, this is the first comprehensive effort
to search for evidence of gene–gene interactions with ANK3
using genome-wide association data coupled with bioinformat-
ics tools. We have found intriguing evidence that interactions of
ANK3 with KCNQ2 may contribute to susceptibility for BP. These
findings warrant further investigation to identify the causally
related variants in these genes and characterize how interactions
between them might contribute to the etiology of BP. This may
be approached through various avenues, including further genet-
ics studies (interaction analyses using sequencing or linkage data),
expression studies (transcriptome or proteomics analyses), or epi-
genetic studies (methylation or histone modification analyses).
These results may be further probed experimentally via animal
models. If the interactions ofANK3withKCNQ2 can be confirmed
to play a role in the etio-pathogenesis of BP, it would motivate a
new avenue of research into a novel therapeutic target for this
disease. This would be advantageous because KCNQ2/KCNQ3
channels have been the focus of extensive pharmacologic research
in relation to epilepsy, and several compounds that act either as
activators or inhibitors of the complex have already been identi-
fied and are in various stages of clinical investigation (Miceli et al.,
2008).
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APPENDIX
Table A1 | Genotype frequencies by affection status across samples.
Gene SNP Genotype GAIN-TGEN WTCCC German
Controls Cases Controls Cases Controls Cases
KCNQ2 rs2297385 0 0.8601 0.8632 0.8752 0.8683 0.8550 0.8682
1 0.1329 0.1323 0.1212 0.1290 0.1374 0.1271
2 0.0070 0.0045 0.0037 0.0027 0.0076 0.0047
KCNQ2 rs2282150 0 0.8601 0.8627 0.8755 0.8688 0.8580 0.8698
1 0.1329 0.1327 0.1208 0.1285 0.1351 0.1256
2 0.0070 0.0045 0.0037 0.0027 0.0069 0.0047
ANK3 rs10994334 0 0.7189 0.7264 0.7336 0.7238 0.7473 0.7566
1 0.2637 0.2532 0.2480 0.2554 0.2290 0.2248
2 0.0174 0.0205 0.0184 0.0209 0.0237 0.0186
ANK3 rs11814450 0 0.7481 0.7459 0.7553 0.7602 0.7710 0.7736
1 0.2366 0.2382 0.2293 0.2232 0.2107 0.2047
2 0.0153 0.0159 0.0154 0.0166 0.0183 0.0217
ANK3 rs12413099 0 0.7550 0.7495 0.7630 0.7677 0.7870 0.7891
1 0.2303 0.2336 0.2226 0.2173 0.1969 0.1922
2 0.0146 0.0168 0.0144 0.0150 0.0160 0.0186
ANK3 rs12413770 0 0.7495 0.7491 0.7640 0.7650 0.7878 0.7907
1 0.2366 0.2355 0.2216 0.2195 0.1969 0.1907
2 0.0139 0.0155 0.0144 0.0155 0.0153 0.0186
ANK3 rs12416179 0 0.7189 0.7264 0.7336 0.7238 0.7473 0.7566
1 0.2630 0.2532 0.2480 0.2554 0.2290 0.2248
2 0.0181 0.0205 0.0184 0.0209 0.0237 0.0186
ANK3 rs1459730 0 0.7467 0.7464 0.7593 0.7618 0.7779 0.7814
1 0.2366 0.2368 0.2260 0.2216 0.2046 0.2000
2 0.0167 0.0168 0.0147 0.0166 0.0176 0.0186
ANK3 rs16914663 0 0.7543 0.7536 0.7627 0.7671 0.7870 0.7891
1 0.2310 0.2300 0.2230 0.2179 0.1969 0.1922
2 0.0146 0.0164 0.0144 0.0150 0.0160 0.0186
ANK3 rs16914670 0 0.7557 0.7550 0.7634 0.7677 0.7870 0.7891
1 0.2296 0.2286 0.2223 0.2173 0.1969 0.1922
2 0.0146 0.0164 0.0144 0.0150 0.0160 0.0186
ANK3 rs16914683 0 0.7557 0.7541 0.7634 0.7677 0.7870 0.7891
1 0.2296 0.2300 0.2223 0.2173 0.1969 0.1922
2 0.0146 0.0159 0.0144 0.0150 0.0160 0.0186
ANK3 rs16914687 0 0.7543 0.7491 0.7627 0.7677 0.7870 0.7891
1 0.2303 0.2345 0.2230 0.2173 0.1969 0.1922
2 0.0153 0.0164 0.0144 0.0150 0.0160 0.0186
ANK3 rs16914968 0 0.7196 0.7241 0.7350 0.7238 0.7534 0.7581
1 0.2624 0.2559 0.2470 0.2543 0.2237 0.2248
2 0.0181 0.0200 0.0180 0.0219 0.0229 0.0171
(Continued)
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Table A1 | Continued
Gene SNP Genotype GAIN-TGEN WTCCC German
Controls Cases Controls Cases Controls Cases
ANK3 rs17233373 0 0.7495 0.7477 0.7640 0.7650 0.7870 0.7891
1 0.2366 0.2368 0.2216 0.2195 0.1977 0.1922
2 0.0139 0.0155 0.0144 0.0155 0.0153 0.0186
ANK3 rs7093272 0 0.7537 0.7545 0.7630 0.7677 0.7870 0.7891
1 0.2310 0.2286 0.2226 0.2173 0.1969 0.1922
2 0.0153 0.0168 0.0144 0.0150 0.0160 0.0186
ANK3 rs7910984 0 0.7481 0.7468 0.7510 0.7570 0.7870 0.7891
1 0.2380 0.2377 0.2343 0.2270 0.1977 0.1922
2 0.0139 0.0155 0.0147 0.0161 0.0153 0.0186
ANK3 rs7911285 0 0.7495 0.7477 0.7640 0.7650 0.7870 0.7891
1 0.2366 0.2368 0.2216 0.2195 0.1977 0.1922
2 0.0139 0.0155 0.0144 0.0155 0.0153 0.0186
ANK3 rs898329 0 0.7495 0.7491 0.7644 0.7650 0.7878 0.7907
1 0.2366 0.2355 0.2213 0.2195 0.1969 0.1907
2 0.0139 0.0155 0.0144 0.0155 0.0153 0.0186
ANK3* rs10994180 0 0.5477 0.5382 0.5270 0.5316 0.5328 0.5116
1 0.3855 0.4009 0.4276 0.4202 0.3939 0.4202
2 0.0668 0.0609 0.0454 0.0482 0.0733 0.0682
ANK3* rs10740006 0 0.5484 0.5391 0.5274 0.5316 0.5328 0.5116
1 0.3848 0.4000 0.4272 0.4202 0.3939 0.4202
2 0.0668 0.0609 0.0454 0.0482 0.0733 0.0682
ANK3* rs10821668 0 0.5470 0.5395 0.5277 0.5316 0.5328 0.5116
1 0.3862 0.3995 0.4269 0.4202 0.3939 0.4202
2 0.0668 0.0609 0.0454 0.0482 0.0733 0.0682
ANK3* rs10994181 0 0.5470 0.5386 0.5270 0.5310 0.5321 0.5116
1 0.3862 0.4000 0.4276 0.4208 0.3947 0.4202
2 0.0668 0.0614 0.0454 0.0482 0.0733 0.0682
ANK3* rs10994406 0 0.9812 0.9818 0.9913 0.9904 0.9511 0.9442
1 0.0188 0.0173 0.0083 0.0096 0.0481 0.0558
2 0.0000 0.0009 0.0003 0.0000 0.0008 0.0000
*These five ANK3 SNPs significantly interact with the driving KCNQ2 SNPs in the German sample.
Genotype frequencies by affection status across the three samples for the two KCNQ2 SNPs and the 16 ANK3 SNPs, combinations of which constitute the 28
significant pair-wise interactions in the GAIN-TGEN discovery and WTCCC replication samples. Additionally listed are the five ANK3 SNPs that interact with the two
“driving” KCNQ2 SNPs that were found to be significant in the German sample.
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